Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra). (Q45245267)

11 December 2017

title

Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra). (English)

1 reference

11 December 2017

1 reference

1 reference

1 reference

Alain Lafeuillade

1

1 reference

11 December 2017

Gilles Hittinger

2

1 reference

11 December 2017

Gisèle Philip

3

1 reference

11 December 2017

Véronique Lambry

4

1 reference

11 December 2017

Patricia Jolly

5

1 reference

11 December 2017

Cécile Poggi

6

1 reference

11 December 2017

publication date

1 November 2004

1 reference

11 December 2017

1 reference

11 December 2017

volume

5

1 reference

11 December 2017

issue

6

1 reference

11 December 2017

page(s)

392-398

1 reference

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1310%2FQ0TG-0V50-9JML-638U

HIV protease inhibitors acutely impair glucose-stimulated insulin release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FQ0TG-0V50-9JML-638U

Combination antiretroviral therapy and the risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FQ0TG-0V50-9JML-638U

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FQ0TG-0V50-9JML-638U

Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FQ0TG-0V50-9JML-638U

Impact of Various Antiretroviral Drugs and Their Plasma Concentrations on Plasma Lipids in Heavily Pretreated HIV-Infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FQ0TG-0V50-9JML-638U

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FQ0TG-0V50-9JML-638U

Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FQ0TG-0V50-9JML-638U

Evolution of lipid abnormalities in patients switched from stavudine- to tenofovir-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FQ0TG-0V50-9JML-638U

Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FQ0TG-0V50-9JML-638U

Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FQ0TG-0V50-9JML-638U

Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FQ0TG-0V50-9JML-638U

10.1310/Q0TG-0V50-9JML-638U

21 January 2018

Identifiers

DOI

1 reference

11 December 2017

1 reference